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In November 2014, a 79 year-old gentleman was admitted to a Scottish hospital with a 
widespread vesicular rash consistent with varicella zoster virus (VZV) infection. He was 
diagnosed with chronic lymphocytic leukaemia in January 2012 and finished six cycles of 
fludarabine, cyclophosphamide and rituximab in April 2014. Five weeks prior to admission he 
received the zoster vaccine as part of the immunisation programme against shingles. 
Afterwards, he gradually developed malaise and, four weeks after vaccination, some vesicles 
appeared at the injection site. On admission, he was pyrexial at 41ºC and presented a 
vesicular rash on his right upper arm, torso and extremities. He showed no respiratory 
distress and a chest X-ray was unremarkable. He was pancytopenic with haemoglobin 109 
g/L, white cell count 1.3x109/L (lymphocytes 0.6x109/L) and platelets 55x109/L. Intravenous 
(iv) antimicrobial therapy was started with piperacilin/tazobactam, gentamicin and high dose iv 
aciclovir (10 mg/kg tds). Human normal immunoglobulin (HNIG) was added on day three (400 
mg/kg every other day for a total of five doses). The patient continued to develop new 
vesicular lesions yet remained stable with neither clinical nor radiological evidence of 
systemic involvement. On day six, he suffered an abrupt clinical deterioration and was 
transferred to the Intensive Care Unit (ITU) for mechanical ventilation, inotropic support and 
acute renal failure management. A chest X-ray revealed patchy consolidation throughout both 
lungs.  Aciclovir was increased (iv 20 mg/kg tds) and ganciclovir (iv 5 mg/kg bd) was added in 
case of possible cytomegalovirus (CMV) superadded pneumonititis. Ganciclovir was stopped 
24 hours later as CMV testing was negative. Bronchoalvelar lavage (BAL), vesicle fluid and 
plasma were positive by polymerase chain reaction (PCR) for VZV. BAL was negative for 
respiratory viruses and culture for bacteria and fungi were also negative. After four days in the 
ITU, no further vesicles had developed. Although the patient was extubated and VZV became 
negative in plasma and BAL by day 12 in ITU, he subsequently deteriorated developing multi-
organ failure and dying 25 days after admission. VZV Oka vaccine strain (vOka) was detected 
in vesicle fluid using PCR.  
   VZV is an ubiquitous alphaherpesvirus which causes vesicular rash. Herpes zoster (HZ) or 
shingles results from reactivation of latent VZV in nerve-root ganglia, usually many years after 
the primary VZV infection (varicella or chicken pox). HZ is typically restricted to one or two 
contiguous dermatomes, but can be extensive in elderly and immunocompromised 
individuals. HZ complications include postherpetic neuralgia, HZ ophthalmicus, stroke and 
meningoencephalitis1. Life threatening disseminated disease can occur in severely 
immunosuppressed patients. The  zoster vaccine has been shown to be effective in 
preventing both zoster and postherpetci neuralgia, whith the result that immunisation 
programmes were introduced in the United States in 20062  and subsequently in other 
European countries . Zoster vaccine contains the same VZV Oka live, attenuated strain in the 
varicella vaccine, formulated with a significantly higher dose. The vaccine is  well tolerated 
and safe2,3  however, a single death following the zoster vaccination has been reported in an 
immunosuppressed patient rted3. The UK zoster immunisation programme started in 
September 2013, initially targeting people aged 70 (routine programme) and 78 or 79 (catch 
up programme) and coverage rates of around 60% have been reached in the target age 
groups.  While varicella vaccine is licensed in some immunocompromised populations, 
recommendations for the use of zoster vaccine in the immunocompromised is mixed2,4,5.  
Even where limited use in the immunocompromised is recommended, zoster vaccine is 
contraindicated for individuals with haematological malignancies4. Confusingly, current 
recommendations also suggest that zoster vaccine can be given six months after the end of 
chemotherapy or radiotherapy4, as was the case for this patient.  
   PCR results demonstrate the possibility of the zoster vaccine causing widespread lethal 
infection in the immunocompromised. If a varicella rash develops after inadvertent zoster 
vaccination, aciclovir should be instigated urgently. To our knowledge, this is the first lethal 
case following zoster vaccination in Europe and reinforces existing advice not to immunise 
individuals with haematological malignancies .   
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